Exact Mass: 489.3665

Exact Mass Matches: 489.3665

Found 102 metabolites which its exact mass value is equals to given mass value 489.3665, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Chenodeoxycholylproline

1-(4-{5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanoyl)pyrrolidine-2-carboxylic acid

C29H47NO5 (489.3454)


Chenodeoxycholylproline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylproline consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Proline conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylproline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylproline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Deoxycholylproline

1-(4-{5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanoyl)pyrrolidine-2-carboxylic acid

C29H47NO5 (489.3454)


Deoxycholylproline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylproline consists of the bile acid deoxycholic acid conjugated to the amino acid Proline conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylproline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylproline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Erucylphosphocholine

Docos-13-en-1-yl 2-(trimethylazaniumyl)ethyl phosphoric acid

C27H56NO4P (489.3947)


   

Nirogacestat

2-[(6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino]-N-(1-{1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl}-1H-imidazol-4-yl)pentanimidate

C27H41F2N5O (489.3279)


D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators

   
   
   
   

N-(20-amino-4-hydroxy-4,8,12,17-tetraazaicosyl)-1H-indole-3-acetamide

N-(20-amino-4-hydroxy-4,8,12,17-tetraazaicosyl)-1H-indole-3-acetamide

C26H47N7O2 (489.3791)


   
   

Solaphyllidin|Solaphyllidine

Solaphyllidin|Solaphyllidine

C29H47NO5 (489.3454)


   

N-(20-amino-4,8,12,17-tetraazaicosyl)-4-hydroxy-1H-indole-3-acetamide

N-(20-amino-4,8,12,17-tetraazaicosyl)-4-hydroxy-1H-indole-3-acetamide

C26H47N7O2 (489.3791)


   

Lys Lys Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]hexanamido]-3-hydroxypropanoic acid

C21H43N7O6 (489.3275)


   

Lys Lys Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-hydroxypropanamido]hexanoic acid

C21H43N7O6 (489.3275)


   

Lys Ser Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]hexanamido]hexanoic acid

C21H43N7O6 (489.3275)


   

Ser Lys Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]hexanamido]hexanoic acid

C21H43N7O6 (489.3275)


   

2-pentacosanamidoethanesulfonic acid

2-pentacosanamidoethanesulfonic acid

C27H55NO4S (489.3852)


   

NAT 25:0

N-pentacosanoyl taurine

C27H55NO4S (489.3852)


   

tributylhexadecylammonium bromide

tributylhexadecylammonium bromide

C28H60BrN (489.3909)


   

Carboprost tromethamine

Carboprost tromethamine

C25H47NO8 (489.3302)


D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue

   

N,N,N-Triheptyl-1-heptanaminium bromide

N,N,N-Triheptyl-1-heptanaminium bromide

C28H60BrN (489.3909)


   

Poly(diallyldimethylammonium chloride)

Poly(diallyldimethylammonium chloride)

C24H54Cl3N3 (489.3383)


   

Nirogacestat

Nirogacestat

C27H41F2N5O (489.3279)


D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators C471 - Enzyme Inhibitor

   

1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9alpha,11beta,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-Oate

1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9alpha,11beta,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-Oate

C25H47NO8 (489.3302)


   

Deoxycholylproline

Deoxycholylproline

C29H47NO5 (489.3454)


   

Chenodeoxycholylproline

Chenodeoxycholylproline

C29H47NO5 (489.3454)


   

[(E)-docos-13-enyl] 2-(trimethylazaniumyl)ethyl phosphate

[(E)-docos-13-enyl] 2-(trimethylazaniumyl)ethyl phosphate

C27H56NO4P (489.3947)


   

(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one

(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one

C28H47N3O4 (489.3566)


   

N-[(4S,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4S,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(3S)-5-methyl-2-oxohexan-3-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamic acid (phenylmethyl) ester

N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(3S)-5-methyl-2-oxohexan-3-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamic acid (phenylmethyl) ester

C27H43N3O5 (489.3203)


   

(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one

(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one

C28H47N3O4 (489.3566)


   

(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one

(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one

C28H47N3O4 (489.3566)


   

N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

C27H43N3O5 (489.3203)


   

N-[(4S,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4S,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(4R,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4R,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(4R,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4R,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

C27H43N3O5 (489.3203)


   

N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

C27H43N3O5 (489.3203)


   

N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

C27H43N3O5 (489.3203)


   

N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

C27H43N3O5 (489.3203)


   

N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide

C27H43N3O5 (489.3203)


   

N-[(4S,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4S,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(4R,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4R,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(4S,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4S,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   

N-[(4R,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(4R,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

C27H43N3O5 (489.3203)


   
   

HexCer 8:1;2O/11:0

HexCer 8:1;2O/11:0

C25H47NO8 (489.3302)


   

HexCer 12:1;2O/7:0

HexCer 12:1;2O/7:0

C25H47NO8 (489.3302)


   

HexCer 17:1;2O/2:0

HexCer 17:1;2O/2:0

C25H47NO8 (489.3302)


   

HexCer 15:1;2O/4:0

HexCer 15:1;2O/4:0

C25H47NO8 (489.3302)


   

HexCer 16:1;2O/3:0

HexCer 16:1;2O/3:0

C25H47NO8 (489.3302)


   

HexCer 11:1;2O/8:0

HexCer 11:1;2O/8:0

C25H47NO8 (489.3302)


   

HexCer 10:1;2O/9:0

HexCer 10:1;2O/9:0

C25H47NO8 (489.3302)


   

HexCer 13:1;2O/6:0

HexCer 13:1;2O/6:0

C25H47NO8 (489.3302)


   

HexCer 14:1;2O/5:0

HexCer 14:1;2O/5:0

C25H47NO8 (489.3302)


   

HexCer 9:1;2O/10:0

HexCer 9:1;2O/10:0

C25H47NO8 (489.3302)


   

NAGly 16:4/11:0

NAGly 16:4/11:0

C29H47NO5 (489.3454)


   

2-aminoethyl [2-hydroxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propyl] hydrogen phosphate

2-aminoethyl [2-hydroxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propyl] hydrogen phosphate

C25H48NO6P (489.3219)


   

3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dodecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dodecane-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-3-hydroxy-2-(undecanoylamino)pentadec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(undecanoylamino)pentadec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tridecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tridecane-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-3-hydroxy-2-(pentadecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(pentadecanoylamino)undec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-2-(decanoylamino)-3-hydroxyhexadec-4-ene-1-sulfonic acid

(E)-2-(decanoylamino)-3-hydroxyhexadec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydecane-1-sulfonic acid

2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydecane-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-3-hydroxy-2-(tridecanoylamino)tridec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(tridecanoylamino)tridec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-3-hydroxy-2-(tetradecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(tetradecanoylamino)dodec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-2-(hexadecanoylamino)-3-hydroxydec-4-ene-1-sulfonic acid

(E)-2-(hexadecanoylamino)-3-hydroxydec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

(E)-2-(dodecanoylamino)-3-hydroxytetradec-4-ene-1-sulfonic acid

(E)-2-(dodecanoylamino)-3-hydroxytetradec-4-ene-1-sulfonic acid

C26H51NO5S (489.3488)


   

3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]undecane-1-sulfonic acid

C26H51NO5S (489.3488)


   
   
   

NA-Cit 22:4(7Z,10Z,13Z,16Z)

NA-Cit 22:4(7Z,10Z,13Z,16Z)

C28H47N3O4 (489.3566)


   

NA-DOPA 20:1(11Z)

NA-DOPA 20:1(11Z)

C29H47NO5 (489.3454)


   

NA-Taurine 25:0

NA-Taurine 25:0

C27H55NO4S (489.3852)


   
   
   
   
   
   

LPE P-20:2 or LPE O-20:3

LPE P-20:2 or LPE O-20:3

C25H48NO6P (489.3219)


   

CerP 14:2;O2/11:0

CerP 14:2;O2/11:0

C25H48NO6P (489.3219)


   

CerP 15:2;O2/10:0

CerP 15:2;O2/10:0

C25H48NO6P (489.3219)


   
   

ST 27:2;O3;Gly

ST 27:2;O3;Gly

C29H47NO5 (489.3454)


   

ST 28:1;O2;Gly

ST 28:1;O2;Gly

C30H51NO4 (489.3818)


   

7-hydroxy-1-[1-(3-hydroxy-5-methylpiperidin-2-yl)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

7-hydroxy-1-[1-(3-hydroxy-5-methylpiperidin-2-yl)ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C29H47NO5 (489.3454)


   

(2r)-2-(2-{[(3r,4r,5s,7s,16s)-17-amino-4,16-dihydroxy-3,7-dimethylheptadecan-5-yl]oxy}-2-oxoethyl)butanedioic acid

(2r)-2-(2-{[(3r,4r,5s,7s,16s)-17-amino-4,16-dihydroxy-3,7-dimethylheptadecan-5-yl]oxy}-2-oxoethyl)butanedioic acid

C25H47NO8 (489.3302)


   

2-[(3r,4as,8s,10ar,10bs)-7,7,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl]propan-2-ol

2-[(3r,4as,8s,10ar,10bs)-7,7,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl]propan-2-ol

C33H47NO2 (489.3607)


   

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(1h-indol-3-yl)ethanimidic acid

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(1h-indol-3-yl)ethanimidic acid

C26H47N7O2 (489.3791)


   

(1r,2r,3as,3br,5ar,7s,9ar,9bs,11as)-7-hydroxy-1-[(1s)-1-[(2r,3s,5r)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

(1r,2r,3as,3br,5ar,7s,9ar,9bs,11as)-7-hydroxy-1-[(1s)-1-[(2r,3s,5r)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C29H47NO5 (489.3454)


   

2-[(3s,4as,8s,10ar,10bs)-7,7,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl]propan-2-ol

2-[(3s,4as,8s,10ar,10bs)-7,7,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl]propan-2-ol

C33H47NO2 (489.3607)


   

(1s,4s,7s)-9-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-6-hydroxy-4-isopropyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

(1s,4s,7s)-9-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-6-hydroxy-4-isopropyl-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one

C31H43N3O2 (489.3355)


   

n-(20-amino-4,8,12,17-tetraazaicosan-1-yl)-2-(4-hydroxy-1h-indol-2-yl)ethanimidic acid

n-(20-amino-4,8,12,17-tetraazaicosan-1-yl)-2-(4-hydroxy-1h-indol-2-yl)ethanimidic acid

C26H47N7O2 (489.3791)


   

2-{2-[(17-amino-4,16-dihydroxy-3,7-dimethylheptadecan-5-yl)oxy]-2-oxoethyl}butanedioic acid

2-{2-[(17-amino-4,16-dihydroxy-3,7-dimethylheptadecan-5-yl)oxy]-2-oxoethyl}butanedioic acid

C25H47NO8 (489.3302)


   

2-[(3s,4as,8s,10ar,10bs)-7,7,10b-trimethyl-8-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl]propan-2-ol

2-[(3s,4as,8s,10ar,10bs)-7,7,10b-trimethyl-8-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl]propan-2-ol

C33H47NO2 (489.3607)


   

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(1h-indol-2-yl)ethanimidic acid

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(1h-indol-2-yl)ethanimidic acid

C26H47N7O2 (489.3791)


   

2-(7,7,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl)propan-2-ol

2-(7,7,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl)propan-2-ol

C33H47NO2 (489.3607)


   

(3s,6r)-3-{[5,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-isopropyl-3,6-dihydropyrazine-2,5-diol

(3s,6r)-3-{[5,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-isopropyl-3,6-dihydropyrazine-2,5-diol

C31H43N3O2 (489.3355)


   

3-{[5,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-isopropyl-3,6-dihydropyrazine-2,5-diol

3-{[5,7-bis(3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-6-isopropyl-3,6-dihydropyrazine-2,5-diol

C31H43N3O2 (489.3355)


   

2-(7,7,10b-trimethyl-8-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl)propan-2-ol

2-(7,7,10b-trimethyl-8-{[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-naphtho[2,1-b]pyran-3-yl)propan-2-ol

C33H47NO2 (489.3607)


   

(1r,2r,3ar,3br,5ar,7s,9ar,9br,11as)-7-hydroxy-1-[(1s)-1-[(2r,3s,5r)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

(1r,2r,3ar,3br,5ar,7s,9ar,9br,11as)-7-hydroxy-1-[(1s)-1-[(2r,3s,5r)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-6-oxo-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C29H47NO5 (489.3454)


   

2-(7,7a,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-azuleno[5,4-b]pyran-3-yl)propan-2-ol

2-(7,7a,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-azuleno[5,4-b]pyran-3-yl)propan-2-ol

C33H47NO2 (489.3607)


   

2-[(3r,4ar,7ar,8r,10as,10br)-7,7a,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-azuleno[5,4-b]pyran-3-yl]propan-2-ol

2-[(3r,4ar,7ar,8r,10as,10br)-7,7a,10b-trimethyl-8-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methyl}-1h,2h,3h,4ah,5h,8h,9h,10h,10ah-azuleno[5,4-b]pyran-3-yl]propan-2-ol

C33H47NO2 (489.3607)